1. Home
  2. ADPT vs ITGR Comparison

ADPT vs ITGR Comparison

Compare ADPT & ITGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$25.31

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Logo Integer Holdings Corporation

ITGR

Integer Holdings Corporation

N/A

Current Price

$125.33

Market Cap

4.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADPT
ITGR
Founded
2009
1970
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
4.3B
IPO Year
2019
2000

Fundamental Metrics

Financial Performance
Metric
ADPT
ITGR
Price
$25.31
$125.33
Analyst Decision
Strong Buy
Buy
Analyst Count
9
7
Target Price
$17.78
$91.14
AVG Volume (30 Days)
2.3M
1.6M
Earning Date
05-05-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
63.89
N/A
EPS
N/A
1.17
Revenue
$276,976,000.00
$1,853,637,000.00
Revenue This Year
$3.98
$1.69
Revenue Next Year
$22.72
$6.53
P/E Ratio
N/A
$107.09
Revenue Growth
54.77
7.98
52 Week Low
$12.00
$62.00
52 Week High
$26.87
$126.14

Technical Indicators

Market Signals
Indicator
ADPT
ITGR
Relative Strength Index (RSI) 59.47 80.16
Support Level $23.92 $82.09
Resistance Level $26.16 $126.14
Average True Range (ATR) 1.01 0.33
MACD -0.05 -1.08
Stochastic Oscillator 62.71 72.31

Price Performance

Historical Comparison
ADPT
ITGR

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

About ITGR Integer Holdings Corporation

Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.

Share on Social Networks: